CA2467731A1 - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates Download PDF

Info

Publication number
CA2467731A1
CA2467731A1 CA002467731A CA2467731A CA2467731A1 CA 2467731 A1 CA2467731 A1 CA 2467731A1 CA 002467731 A CA002467731 A CA 002467731A CA 2467731 A CA2467731 A CA 2467731A CA 2467731 A1 CA2467731 A1 CA 2467731A1
Authority
CA
Canada
Prior art keywords
conjugate
hgh
group
peg
growth hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002467731A
Other languages
English (en)
French (fr)
Inventor
Rory F. Finn
Wei Lao
Ned R. Siegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2467731A1 publication Critical patent/CA2467731A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002467731A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates Abandoned CA2467731A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
US60/331,907 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
CA2467731A1 true CA2467731A1 (en) 2003-05-30

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467731A Abandoned CA2467731A1 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (cg-RX-API-DMAC7.html)
JP (2) JP2005525302A (cg-RX-API-DMAC7.html)
KR (2) KR20070072924A (cg-RX-API-DMAC7.html)
CN (1) CN1608079A (cg-RX-API-DMAC7.html)
AP (1) AP2004003050A0 (cg-RX-API-DMAC7.html)
AU (1) AU2002356990A1 (cg-RX-API-DMAC7.html)
BR (1) BR0214451A (cg-RX-API-DMAC7.html)
CA (1) CA2467731A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580794A2 (cg-RX-API-DMAC7.html)
EA (2) EA200700431A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP045114A (cg-RX-API-DMAC7.html)
GE (1) GEP20063860B (cg-RX-API-DMAC7.html)
HR (1) HRP20040448A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0500997A2 (cg-RX-API-DMAC7.html)
IL (1) IL162031A0 (cg-RX-API-DMAC7.html)
IS (1) IS7268A (cg-RX-API-DMAC7.html)
MA (1) MA27544A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04004809A (cg-RX-API-DMAC7.html)
NO (1) NO20042182L (cg-RX-API-DMAC7.html)
OA (1) OA13063A (cg-RX-API-DMAC7.html)
PL (1) PL374354A1 (cg-RX-API-DMAC7.html)
RS (1) RS53104A (cg-RX-API-DMAC7.html)
TN (1) TNSN04090A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003044056A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403907B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
JP4764630B2 (ja) 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2033662B1 (en) * 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
AU2005278903A1 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
NZ555308A (en) 2004-12-22 2010-10-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
JP2008525032A (ja) * 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
WO2006084888A2 (en) 2005-02-10 2006-08-17 Novo Nordisk A/S C-terminally pegylated growth hormones
AU2006237329B2 (en) 2005-04-18 2012-04-12 Novo Nordisk A/S IL-21 variants
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
HRP20110404T1 (hr) * 2005-11-08 2011-08-31 Ambrx Ubrzivači za modifikaciju ne-prirodnih aminokiselina i polipeptida ne-prirodnih aminokiselina
KR101423898B1 (ko) 2005-12-14 2014-07-28 암브룩스, 인코포레이티드 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
WO2008003750A2 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (zh) * 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
JP5458416B2 (ja) * 2008-04-03 2014-04-02 バイオスティード ジーン エクスプレッション テック. カンパニー リミテッド 二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
KR101104574B1 (ko) * 2008-05-14 2012-01-11 성균관대학교산학협력단 폴리에틸렌글리콜로 화학적으로 수식된 인간 성장 호르몬, 이의 제조방법 및 용도
JP5639585B2 (ja) * 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション ペプチド−ポリマー共役体
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (ru) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
JP2013533217A (ja) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Peg化c−ペプチド
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (ru) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Ковалентный конъюгат полиэтиленгликоля с гормоном роста человека
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
AU2015342908B2 (en) 2014-11-06 2021-06-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
IL254389B2 (en) * 2015-03-11 2023-03-01 Nektar Therapeutics Polymer conjugates and the il–7 group
KR102152437B1 (ko) 2015-09-18 2020-09-07 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 장시간 작용형 아드레노메둘린 유도체
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー/エス 1日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
CN114539384B (zh) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2113354T3 (es) * 1990-05-04 1998-05-01 American Cyanamid Co Estabilizacion de somatotropinas y otras proteinas por modificacion de residuos de cisteina.
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
ATE455171T1 (de) * 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) * 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子

Also Published As

Publication number Publication date
AU2002356990A1 (en) 2003-06-10
WO2003044056A2 (en) 2003-05-30
CO5580794A2 (es) 2005-11-30
AP2004003050A0 (en) 2004-06-30
EA008505B1 (ru) 2007-06-29
ECSP045114A (es) 2004-07-23
OA13063A (en) 2006-11-10
MA27544A1 (fr) 2005-10-03
WO2003044056A3 (en) 2003-08-21
HUP0500997A2 (en) 2007-11-28
KR20070072924A (ko) 2007-07-06
RS53104A (sr) 2006-10-27
EP1453859A2 (en) 2004-09-08
NO20042182L (no) 2004-08-11
EA200400565A1 (ru) 2005-06-30
JP2006321808A (ja) 2006-11-30
GEP20063860B (en) 2006-06-26
KR20050044858A (ko) 2005-05-13
TNSN04090A1 (fr) 2006-06-01
JP2005525302A (ja) 2005-08-25
PL374354A1 (en) 2005-10-17
ZA200403907B (en) 2007-12-27
EA200700431A1 (ru) 2008-02-28
MXPA04004809A (es) 2004-08-11
HRP20040448A2 (en) 2006-02-28
IL162031A0 (en) 2005-11-20
BR0214451A (pt) 2006-05-30
CN1608079A (zh) 2005-04-20
IS7268A (is) 2004-05-17

Similar Documents

Publication Publication Date Title
AU2002356990A1 (en) Chemically-modified human growth hormone conjugates
US20030171285A1 (en) Chemically-modified human growth hormone conjugates
EP1715887B1 (en) N-terminally monopegylated human growth hormone conjugates, process for their preparation, and use thereof
EP1789092A2 (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
US20040127417A1 (en) N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040038892A1 (en) Chemically-modified human growth hormone conjugates
WO2006102659A2 (en) CONJUGATES OF AN hGH MOIETY AND A POLYMER
US20090203589A1 (en) Chemically modified human growth hormone receptor antagonist conjugates
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
HK1072058A (en) Chemically-modified human growth hormone conjugates
HK1104913A (en) Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
MXPA06008888A (en) N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued